Additional mechanisms of acquired resistance to EGFR-TKIs include activation of insulin-like growth factor-1 receptor (IGF-1R), amplification of MET and HER2, upregulation of the AXL receptor or its ligand, activating mutations in PIK3CA and BRAF, and SCLC transformation6,10,11. Here, IGF1R is linked to small cell lung carcinoma.